XNCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Xencor Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$23.19+0.34 (+1.49%)
Close on Oct 19, 2026
- Market cap
- $1.76B
- P/E (TTM)
- –
- Dividend yield
- –
Xencor Inc revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalties | $89.07M | $66.46M | $80.28M | $76.63M | $73.43M | $70.23M | $67.49M | $63.00M | $59.70M | $57.59M | $55.80M | $57.80M | 84.9% | +21.3% |
| Milestone | $15.80M | $30.80M | $45.30M | $73.50M | $73.50M | $48.50M | $34.50M | $28.00M | $74.00M | $84.00M | $88.50M | $61.50M | 15.1% | -78.5% |
| License | $100.00K | $100.00K | $0 | $0 | $0 | $8.50M | $8.50M | – | – | – | – | – | 0.1% | – |
| Non-Cash Royalty | – | – | – | – | – | – | – | $63.30M | $45.50M | $30.10M | $14.60M | – | – | – |
By region
From the segment and revenue-disaggregation notes of Xencor's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.